ZB-168 is a fully human, anti-IL7Rα monoclonal antibody with best-in-class potential.
ZB-168 potently inhibits two critical immune pathways: IL7 and TSLP
Zura Bio holds an exclusive worldwide license for the development and commercialization of ZB-168 in all indications.
It is the only anti-IL7Rα program to date with clinical data showing impact on key T-cell subpopulations, underscoring its potential applicability in a broad range of T-cell mediated diseases and atopic diseases.
IL7 and TLSP pathways
IL7Rα: A unique target for modulating two key immune pathways
IL7 is a critical modulator of T-cell homeostasis,
proliferation, and survival
Inhibition of IL7Rα promotes a normalisation in
Polymorphism in IL7Rα associated with multiple disease states, including T1DM, MS, UC, Sarcoidosis PBC and AA
Is a regulator of Th2 immune response
Is involved in immunity at barrier surfaces
(skin, airways, gut)
Is clinically validated for the treatment of
Is under clinical investigation in CSU, COPD,
and chronic rhinosinusitis
Williams, J.H., Udata, C., Ganguly, B.J. et al. AAPS J 22, 23 (2020)
Dai, Zhenpeng et al. Science advances vol. 7,14 eabd1866. 2 Apr. 2021